Cyramza Approval History
- FDA approved: Yes (First approved April 21st, 2014)
- Brand name: Cyramza
- Generic name: ramucirumab
- Company: Eli Lilly and Company
- Treatment for: Stomach Cancer
Cyramza (ramucirumab) is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated for the treatment of advanced gastric cancer.
FDA Approval History for Cyramza
|Nov 5, 2014||FDA Approves Cyramza (ramucirumab) in Combination with Paclitaxel for Advanced Gastric Cancer after Prior Chemotherapy|
|Apr 21, 2014||FDA Approves Cyramza for Stomach Cancer|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.